Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements
Alzheimer’s disease (AD) is the leading cause of dementia, accounting for 60–80% of all cases globally. Hallmark pathologies of AD include the accumulation of amyloid β peptide and phosphorylated tau, leading to neuronal circuit dysfunction, defective axonal transport, and neurotransmitter system (N...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Molecular Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnmol.2025.1518868/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766420956577792 |
|---|---|
| author | Ammara Shaikh Fairus Ahmad Seong Lin Teoh Jaya Kumar Mohamad Fairuz Yahaya |
| author_facet | Ammara Shaikh Fairus Ahmad Seong Lin Teoh Jaya Kumar Mohamad Fairuz Yahaya |
| author_sort | Ammara Shaikh |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the leading cause of dementia, accounting for 60–80% of all cases globally. Hallmark pathologies of AD include the accumulation of amyloid β peptide and phosphorylated tau, leading to neuronal circuit dysfunction, defective axonal transport, and neurotransmitter system (NTS) abnormalities. Disruptions in acetylcholine, GABA, dopamine, serotonin, and glutamate levels, as well as the loss of cholinergic, GABAergic, and monoaminergic neurons, contribute to the progression of AD. Additionally, neurotrophic factors like brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are significantly reduced in AD, impacting neuronal health and synaptic integrity. This review highlights the emerging role of neurotrophic factor alpha 1 (NF-α1), also known as carboxypeptidase E, in AD. NF-α1 shows neuroprotective and neurogenesis-promoting properties, offering potential for therapeutic interventions. The review compares NF-α1 gene therapy with other neurotrophin-based treatments, providing insights into its efficacy in AD management. |
| format | Article |
| id | doaj-art-bd27557637d3495b8aa804ee3ad90718 |
| institution | DOAJ |
| issn | 1662-5099 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Neuroscience |
| spelling | doaj-art-bd27557637d3495b8aa804ee3ad907182025-08-20T03:04:35ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992025-04-011810.3389/fnmol.2025.15188681518868Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancementsAmmara Shaikh0Fairus Ahmad1Seong Lin Teoh2Jaya Kumar3Mohamad Fairuz Yahaya4Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaDepartment of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaDepartment of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaDepartment of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaDepartment of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaAlzheimer’s disease (AD) is the leading cause of dementia, accounting for 60–80% of all cases globally. Hallmark pathologies of AD include the accumulation of amyloid β peptide and phosphorylated tau, leading to neuronal circuit dysfunction, defective axonal transport, and neurotransmitter system (NTS) abnormalities. Disruptions in acetylcholine, GABA, dopamine, serotonin, and glutamate levels, as well as the loss of cholinergic, GABAergic, and monoaminergic neurons, contribute to the progression of AD. Additionally, neurotrophic factors like brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are significantly reduced in AD, impacting neuronal health and synaptic integrity. This review highlights the emerging role of neurotrophic factor alpha 1 (NF-α1), also known as carboxypeptidase E, in AD. NF-α1 shows neuroprotective and neurogenesis-promoting properties, offering potential for therapeutic interventions. The review compares NF-α1 gene therapy with other neurotrophin-based treatments, providing insights into its efficacy in AD management.https://www.frontiersin.org/articles/10.3389/fnmol.2025.1518868/fullAlzheimer’s diseaseamyloid β peptideneurotransmitter system (NTS) abnormalitiesneurotrophic factor alpha 1 (NF-α1)carboxypeptidase Egene therapy in AD |
| spellingShingle | Ammara Shaikh Fairus Ahmad Seong Lin Teoh Jaya Kumar Mohamad Fairuz Yahaya Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements Frontiers in Molecular Neuroscience Alzheimer’s disease amyloid β peptide neurotransmitter system (NTS) abnormalities neurotrophic factor alpha 1 (NF-α1) carboxypeptidase E gene therapy in AD |
| title | Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements |
| title_full | Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements |
| title_fullStr | Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements |
| title_full_unstemmed | Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements |
| title_short | Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements |
| title_sort | neurotrophic factor alpha 1 gene therapy in alzheimer s disease scope and advancements |
| topic | Alzheimer’s disease amyloid β peptide neurotransmitter system (NTS) abnormalities neurotrophic factor alpha 1 (NF-α1) carboxypeptidase E gene therapy in AD |
| url | https://www.frontiersin.org/articles/10.3389/fnmol.2025.1518868/full |
| work_keys_str_mv | AT ammarashaikh neurotrophicfactoralpha1genetherapyinalzheimersdiseasescopeandadvancements AT fairusahmad neurotrophicfactoralpha1genetherapyinalzheimersdiseasescopeandadvancements AT seonglinteoh neurotrophicfactoralpha1genetherapyinalzheimersdiseasescopeandadvancements AT jayakumar neurotrophicfactoralpha1genetherapyinalzheimersdiseasescopeandadvancements AT mohamadfairuzyahaya neurotrophicfactoralpha1genetherapyinalzheimersdiseasescopeandadvancements |